Archive for January 20, 2016

Interim Guidelines for Pregnant Women During a Zika Virus Outbreak — United States, 2016

MMWR Early Release January 19, 2016 V.65 N.2 P.1-4

Emily E. Petersen, MD; J. Erin Staples, MD, PhD; Dana Meaney-Delman, MD, et al.

Corresponding author: Denise Jamieson, djj0@cdc.gov, 770-488-6377.

1Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC; 2Arboviral Diseases Branch, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 3Office of the Director, National Center for Emerging and Zoonotic Infectious Diseases, CDC.

Zika virus is a mosquito-borne flavivirus transmitted primarily by Aedes aegypti mosquitoes. The incidence of Zika virus infection in pregnant women is not currently known, and data on pregnant women infected with Zika virus are limited.

Zika virus infections have been confirmed in infants with microcephaly, and in the current outbreak in Brazil, a marked increase in the number of infants born with microcephaly has been reported.

Because there is neither a vaccine nor prophylactic medications available to prevent Zika virus infection, CDC recommends that all pregnant women consider postponing travel to areas where Zika virus transmission is ongoing.

FULL TEXT

http://www.cdc.gov/mmwr/volumes/65/wr/mm6502e1er.htm?s_cid=mm6502e1er_e

PDF

http://www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6502e1er.pdf

Advertisements

January 20, 2016 at 1:02 pm

Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study

The British Medical Journal DEC 2015

Research

Paul J Turner, clinician scientist and clinical senior lecturer1, honorary consultant2, Jo Southern, clinical research lead2, Nick J Andrews, senior statistician2, Elizabeth Miller, consultant epidemiologist2, Michel Erlewyn-Lajeunesse, consultant paediatric allergist3 on behalf of the SNIFFLE-2 Study Investigators

Abstract

Study question How safe is live attenuated influenza vaccine (LAIV), which contains egg protein, in young people with egg allergy?

 

Methods In this open label, phase IV intervention study, 779 young people (2-18 years) with egg allergy were recruited from 30 UK allergy centres and immunised with LAIV. The cohort included 270 (34.7%) young people with previous anaphylaxis to egg, of whom 157 (20.1%) had experienced respiratory and/or cardiovascular symptoms. 445 (57.1%) had doctor diagnosed asthma or recurrent wheeze. Participants were observed for at least 30 minutes after vaccination and followed-up by telephone 72 hours later. Participants with a history of recurrent wheeze or asthma underwent further follow-up four weeks later. The main outcome measure was incidence of an adverse event within two hours of vaccination in young people with egg allergy.

 

Study answer and limitations No systemic allergic reactions occurred (upper 95% confidence interval for population 0.47% and in participants with anaphylaxis to egg 1.36%). Nine participants (1.2%, 95% CI 0.5% to 2.2%) experienced mild symptoms, potentially consistent with a local, IgE mediated allergic reaction. Delayed events potentially related to the vaccine were reported in 221 participants. 62 participants (8.1%, 95% CI for population 6.3% to 10.3%) experienced lower respiratory tract symptoms within 72 hours, including 29 with parent reported wheeze. No participants were admitted to hospital. No increase in lower respiratory tract symptoms occurred in the four weeks after vaccination (assessed with asthma control test). The study cohort may represent young people with more severe allergy requiring specialist input, since they were recruited from secondary and tertiary allergy centres.

 

What this study adds LAIV is associated with a low risk of systemic allergic reactions in young people with egg allergy. The vaccine seems to be well tolerated in those with well controlled asthma or recurrent wheeze.

 

Funding, competing interests, data sharing This report is independent research commissioned and funded by a Department of Health policy research programme grant to the National Vaccine Evaluation Consortium. Additional funding was provided by the NIHR Clinical Research Networks, Health Protection Scotland (Edinburgh site), and Health & Social Care Services in Northern Ireland (Belfast site). PJT and MEL had support from the Department of Health for the submitted work; PJT has received research grants from the Medical Research Council and NIHR. No additional data available.

 

Study registration ClinicalTrials.gov (NCT02111512) and the EU Clinical Trials Register EudraCT (2014-001537-92).

 

FULL TEXT

http://www.bmj.com/content/351/bmj.h6291

 

PDF

http://www.bmj.com/content/bmj/351/bmj.h6291.full.pdf

January 20, 2016 at 8:44 am


Calendar

January 2016
M T W T F S S
« Dec   Feb »
 123
45678910
11121314151617
18192021222324
25262728293031

Posts by Month

Posts by Category